Sotac Pharmaceuticals Ltd
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
- Market Cap ₹ 138 Cr.
- Current Price ₹ 125
- High / Low ₹ 203 / 88.0
- Stock P/E 29.0
- Book Value ₹ 48.0
- Dividend Yield 0.00 %
- ROCE 11.4 %
- ROE 9.42 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 112 to 144 days.
- Working capital days have increased from 145 days to 248 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 23.41 | 28.68 | 43.44 | 73.15 | 57.98 | 67.11 | 62.38 | |
| 21.46 | 26.70 | 40.58 | 65.13 | 49.73 | 56.92 | 54.70 | |
| Operating Profit | 1.95 | 1.98 | 2.86 | 8.02 | 8.25 | 10.19 | 7.68 |
| OPM % | 8.33% | 6.90% | 6.58% | 10.96% | 14.23% | 15.18% | 12.31% |
| 0.34 | 0.69 | 0.35 | -1.63 | 0.24 | 1.09 | 2.38 | |
| Interest | 0.49 | 0.37 | 0.61 | 0.58 | 0.90 | 1.01 | 1.17 |
| Depreciation | 1.04 | 1.07 | 1.11 | 1.13 | 1.63 | 2.51 | 2.47 |
| Profit before tax | 0.76 | 1.23 | 1.49 | 4.68 | 5.96 | 7.76 | 6.42 |
| Tax % | 0.00% | 0.00% | 0.00% | 29.91% | 24.66% | 25.90% | 25.55% |
| 0.76 | 1.23 | 1.48 | 3.30 | 4.50 | 5.75 | 4.77 | |
| EPS in Rs | 8.00 | 5.35 | 6.43 | 14.35 | 5.59 | 5.20 | 4.32 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 13.94% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | -5% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 1% |
| TTM: | -19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 6% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 15% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.95 | 2.30 | 2.30 | 2.30 | 8.05 | 11.05 | 11.05 |
| Reserves | -0.04 | 1.40 | 2.51 | 4.80 | 12.94 | 37.22 | 41.98 |
| 8.11 | 7.24 | 6.68 | 7.39 | 10.66 | 11.17 | 20.12 | |
| 7.45 | 10.43 | 11.01 | 21.82 | 23.13 | 16.65 | 12.14 | |
| Total Liabilities | 16.47 | 21.37 | 22.50 | 36.31 | 54.78 | 76.09 | 85.29 |
| 7.54 | 6.41 | 6.42 | 8.80 | 14.09 | 17.67 | 16.66 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.20 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 11.50 | 13.33 |
| 8.93 | 14.96 | 16.08 | 27.51 | 36.65 | 46.87 | 55.10 | |
| Total Assets | 16.47 | 21.37 | 22.50 | 36.31 | 54.78 | 76.09 | 85.29 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 2.22 | 3.58 | 8.54 | -19.75 | -6.08 | |||
| -1.07 | -3.28 | -10.93 | -12.53 | -1.89 | |||
| -1.17 | -0.30 | 11.97 | 23.32 | 7.78 | |||
| Net Cash Flow | -0.02 | 0.00 | 9.57 | -8.96 | -0.20 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 72.81 | 107.92 | 52.68 | 62.57 | 72.40 | 119.71 | 144.41 |
| Inventory Days | 42.90 | 39.50 | 40.71 | 35.14 | 87.26 | 88.97 | 84.60 |
| Days Payable | 140.53 | 175.52 | 112.49 | 128.97 | 165.78 | 119.08 | 77.54 |
| Cash Conversion Cycle | -24.81 | -28.10 | -19.10 | -31.25 | -6.12 | 89.59 | 151.47 |
| Working Capital Days | 19.65 | 31.18 | 26.97 | 29.09 | 24.93 | 160.94 | 248.38 |
| ROCE % | 15.53% | 18.72% | 54.66% | 29.74% | 19.76% | 11.45% |
Documents
Announcements
-
Structural Digital Database
30 May 2025 - Submission of SDD compliance certificate for FY ended March 31, 2025 with remedial actions noted.
-
Outcome of Board Meeting-XBRL
28 May 2025 - Sotac Pharmaceuticals Limited has informed regarding Outcome of Board Meeting held on 28-May-2025 for Dividend
-
Dividend
28 May 2025 - Audited FY25 financials approved; final dividend Rs.0.10/share recommended; audit unmodified opinion.
-
Outcome of Board Meeting
28 May 2025 - Sotac Pharma reports FY25 audited results with Rs.1112L PBT, Rs.0.10 final dividend recommended.
-
Board Meeting Intimation
23 May 2025 - Sotac Pharmaceuticals Limited has informed about Board Meeting to be held on 28-May-2025 to consider and approve the Yearly Audited Financial results of the Company …
Business Overview:[1]
SPL specializes in manufacturing a broad range of pharmaceutical products across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins.